HAEMONETICS CORP financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic.
Latest period: Q4 2025.
-
Symbol
-
HAE on NYSE
-
Location
-
Boston, MA
-
Fiscal year end
-
28 March
-
Latest financial report
-
05 Feb 2026
Quick Takeaways
- HAE - HAEMONETICS CORP financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Return On Equity 19%.
What Changed
- Return On Equity YoY change: <span class="text-green-600">+37%</span>.
- Most recent SEC facts end date: 30 Jan 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original Filing
Latest SEC snapshot (2026-01-30) highlights Return On Equity 19.3%, Return On Assets 6.4%, and Operating Margin 21.0%.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
69.2/100
Balanced
Confidence high
Return On Equity
19%
Metric score 66.5/100
Return On Assets
6.4%
Metric score 55.6/100
Financial Health
- Current Ratio
- 1.75x
- Quick Ratio
- 1.04x
- Debt to Equity
- 1.34x
Strengths
Operating Margin, Current Ratio, and Quick Ratio
Watchpoints
Debt-to-equity and Revenues YoY
Key metrics snapshot
Return On Equity
19%
YoY: +37%
Industry median:
-17%
(n=179)
View history
Return On Assets
6.4%
YoY: +27%
Industry median:
-34%
(n=178)
View history
Operating Margin
21%
YoY: +45%
Industry median:
-18%
(n=127)
View history
Current Ratio
1.75x
YoY: -56%
Industry median:
2.36x
(n=176)
View history
Quick Ratio
1.04x
YoY: -51%
Industry median:
1.49x
(n=146)
View history
Debt-to-equity
1.34x
YoY:
Industry median:
0.46x
(n=133)
View history
Revenues YoY
-4%
YoY:
Industry median:
15%
(n=128)
View history
NetIncomeLoss YoY
35%
YoY:
Industry median:
0.49%
(n=168)
View history
Profitability
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Return On Equity
|
19%
|
+37%
|
-17%
(n=179)
|
Q4 2025
|
Q3 2026
|
%
|
|
Return On Assets
|
6.4%
|
+27%
|
-34%
(n=178)
|
Q4 2025
|
Q3 2026
|
%
|
|
Operating Margin
|
21%
|
+45%
|
-18%
(n=127)
|
Q4 2025
|
Q3 2026
|
%
|
Financial Health
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Current Ratio
|
1.75x
|
-56%
|
2.36x
(n=176)
|
Q4 2025
|
Q3 2026
|
x
|
|
Quick Ratio
|
1.04x
|
-51%
|
1.49x
(n=146)
|
Q4 2025
|
Q3 2026
|
x
|
|
Debt-to-equity
|
1.34x
|
|
0.46x
(n=133)
|
Q4 2025
|
|
x
|
Growth
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Revenues YoY
|
-4%
|
|
15%
(n=128)
|
Q4 2025
|
|
%
|
|
NetIncomeLoss YoY
|
35%
|
|
0.49%
(n=168)
|
Q4 2025
|
Q3 2026
|
%
|
Share Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Entity Common Stock, Shares Outstanding
|
46,471,350
|
-7.5%
|
Q4 2025
|
Q3 2026
|
shares
|
|
Common Stock, Shares, Outstanding
|
46,829,249
|
-6.8%
|
Q4 2025
|
Q3 2026
|
shares
|
|
Common Stock, Value, Issued
|
$468,000
|
-6.8%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Weighted Average Number of Shares Outstanding, Basic
|
46,792,000
|
-6.9%
|
Q4 2025
|
Q3 2026
|
shares
|
|
Weighted Average Number of Shares Outstanding, Diluted
|
46,987,000
|
-7.2%
|
Q4 2025
|
Q3 2026
|
shares
|
Additional Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Revenue from Contract with Customer, Excluding Assessed Tax
|
$1,318,275,000
|
-4%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Research and Development Expense
|
$63,625,000
|
+5.6%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Operating Income (Loss)
|
$251,094,000
|
+39%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
|
$227,166,000
|
+38%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Income Tax Expense (Benefit)
|
$51,730,000
|
+49%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Earnings Per Share, Basic
|
3.65
|
+43%
|
Q4 2025
|
Q3 2026
|
USD/shares
|
|
Earnings Per Share, Diluted
|
3.63
|
+43%
|
Q4 2025
|
Q3 2026
|
USD/shares
|
|
Cash and Cash Equivalents, at Carrying Value
|
$363,367,000
|
+13%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Accounts Receivable, after Allowance for Credit Loss, Current
|
$195,707,000
|
-7.7%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Inventory, Net
|
$321,185,000
|
-11%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Assets, Current
|
$943,674,000
|
-6.2%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Deferred Income Tax Assets, Net
|
$7,329,000
|
-8.4%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Property, Plant and Equipment, Net
|
$297,234,000
|
+3.9%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Intangible Assets, Net (Excluding Goodwill)
|
$419,734,000
|
-9.9%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Goodwill
|
$606,825,000
|
+0.26%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Other Assets, Noncurrent
|
$216,094,000
|
+35%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Assets
|
$2,490,890,000
|
-1.6%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Accounts Payable, Current
|
$48,694,000
|
-23%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Employee-related Liabilities, Current
|
$52,099,000
|
+13%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Liabilities, Current
|
$539,868,000
|
+113%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Deferred Income Tax Liabilities, Net
|
$55,979,000
|
-8.9%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Other Liabilities, Noncurrent
|
$63,605,000
|
-29%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Accumulated Other Comprehensive Income (Loss), Net of Tax
|
$34,610,000
|
+38%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Retained Earnings (Accumulated Deficit)
|
$381,091,000
|
-2.8%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Stockholders' Equity Attributable to Parent
|
$911,451,000
|
+0.51%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Liabilities and Equity
|
$2,490,890,000
|
-1.6%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Common Stock, Shares Authorized
|
150,000,000
|
0%
|
Q4 2025
|
Q3 2026
|
shares
|
|
Common Stock, Shares, Issued
|
46,829,249
|
-6.8%
|
Q4 2025
|
Q3 2026
|
shares
|
|
Common Stock, Par or Stated Value Per Share
|
0.01
|
0%
|
Q4 2025
|
Q3 2026
|
USD/shares
|
|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
|
$363,367,000
|
+13%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Depreciation
|
$61,000,000
|
+2.5%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
|
$196,327,000
|
+98%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Property, Plant and Equipment, Gross
|
$836,814,000
|
-3.5%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Amortization of Intangible Assets
|
$51,500,000
|
-7.4%
|
Q4 2025
|
Q3 2026
|
USD
|
|
Share-based Payment Arrangement, Expense
|
$31,637,000
|
-5.1%
|
Q4 2025
|
Q3 2026
|
USD
|
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric |
Weight |
V1 threshold |
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Explore related SEC datasets